milrinone and Blood Pressure, High studies

Research Excerpts

Excerpt	Relevance	Reference
"Intravenous and intra-arterial milrinone as a rescue measure for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has been adopted by several groups, but so far, evidence for the clinical benefit is unclear and effect on brain perfusion is unknown."	8.12	Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Andereggen, L; Berberat, J; Ensner, R; Marbacher, S; Remonda, L; Steiger, HJ, 2022)
" Postoperatively, the patient had persistent sinus tachycardia that was initially unsuccessfully treated with metoprolol."	7.70	Treatment of milrinone-associated tachycardia with beta-blockers. ( Alhashemi, JA; Hooper, J, 1998)
"Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery."	6.73	Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008)
" To elucidate the effect of milrinone on cardiac mitochondria and death, a rat model of catecholamine-induced heart failure was investigated."	4.12	Milrinone effects on cardiac mitochondria, hemodynamics, and death in catecholamine-infused rats. ( Chan, JYH; Hsieh, KS; Lin, IC; Lin, YJ; Lo, MH; Wu, CW; Wu, KLH, 2022)
"Intravenous and intra-arterial milrinone as a rescue measure for delayed cerebral ischemia (DCI) after subarachnoid hemorrhage (SAH) has been adopted by several groups, but so far, evidence for the clinical benefit is unclear and effect on brain perfusion is unknown."	4.12	Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Andereggen, L; Berberat, J; Ensner, R; Marbacher, S; Remonda, L; Steiger, HJ, 2022)
" Postoperatively, the patient had persistent sinus tachycardia that was initially unsuccessfully treated with metoprolol."	3.70	Treatment of milrinone-associated tachycardia with beta-blockers. ( Alhashemi, JA; Hooper, J, 1998)
"Milrinone use is an independent risk factor for postoperative AF after elective cardiac surgery."	2.73	Milrinone use is associated with postoperative atrial fibrillation after cardiac surgery. ( Ball, SK; Brown, NJ; Byrne, JG; Fleming, GA; Greelish, JP; Hoff, SJ; Murray, KT; Petracek, MR; Pretorius, M; Yu, C, 2008)
"The echocardiographic presence of mild aortic regurgitation combined with left ventricular hypocontractility in a structurally normal heart should alert the physician to the presence of underlying hypertension."	1.39	Neonatal circulatory failure due to acute hypertensive crisis: clinical and echocardiographic clues. ( Allegaert, K; Brown, S; Cools, B; Eyskens, B; Gewillig, M; Heying, R; Levtchenko, E; Louw, J; Smits, A; Thewissen, L, 2013)
"4 microM) inhibitory activities, was found to be orally bioavailable with a long duration of action and offered effective protection against mortality in a collagen-epinephrine-induced pulmonary thromboembolism model in mice."	1.28	3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. ( Bruno, JJ; Hirschfeld, DR; Maloney, PJ; Martinez, GR; Walker, KA; Yang, DS, 1992)

Research

Studies (11)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Acute Renal Failure

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (27.27)	18.2507
2000's	3 (27.27)	29.6817
2010's	1 (9.09)	24.3611
2020's	4 (36.36)	2.80

Authors	Studies
Martinez, GR	1
Walker, KA	1
Hirschfeld, DR	1
Bruno, JJ	1
Yang, DS	1
Maloney, PJ	1
Lakhal, K	1
Hivert, A	1
Rozec, B	1
Cadiet, J	1
Abulhasan, YB	1
Ortiz Jimenez, J	1
Teitelbaum, J	1
Angle, MR	1
Lin, IC	1
Wu, CW	1
Lin, YJ	1
Lo, MH	1
Hsieh, KS	1
Chan, JYH	1
Wu, KLH	1
Steiger, HJ	1
Ensner, R	1
Andereggen, L	1
Remonda, L	1
Berberat, J	1
Marbacher, S	1
Louw, J	1
Brown, S	1
Thewissen, L	1
Smits, A	1
Eyskens, B	1
Heying, R	1
Cools, B	1
Levtchenko, E	1
Allegaert, K	1
Gewillig, M	1
Berg, T	1
Degerman, E	1
Tasken, K	1
Fleming, GA	1
Murray, KT	1
Yu, C	1
Byrne, JG	1
Greelish, JP	1
Petracek, MR	1
Hoff, SJ	1
Ball, SK	1
Brown, NJ	1
Pretorius, M	1
Sasaki, N	1
Joashi, UC	1
Vergara, M	1
Saland, JM	1
Love, BA	1
Alhashemi, JA	1
Hooper, J	1
Schoemaker, RG	1
Smits, JF	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
RAAS, Inflammation, and Post-operative AF[NCT00141778]	Phase 2/Phase 3	455 participants (Actual)	Interventional	2005-04-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Percentage of patients with a creatinine concentrations >2.5mg/dl (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average, depending on the study group.

Death

Intervention	percentage of patients (Number)
Placebo	5.4
Ramipril	0.7
Spironolactone	0.7

The percentage of patients in each study arm who died. (NCT00141778)
Timeframe: Measured until the time of hospital discharge

Hypokalemia

Intervention	percentage of patients (Number)
Placebo	1.4
Ramipril	2.0
Spironolactone	0

Percentage of patients who had a serum potassium concentrations <3.5 milliequivalents (mEq)/L (NCT00141778)
Timeframe: Measured until the time of hospital discharge, which was an average of 5.7 to 6.8 days depending on the treatment arm.

Hypotension

Intervention	percentage of patients (Number)
Placebo	11.6
Ramipril	13.8
Spironolactone	6.8

Percentage of patients with hypotension defined as a systolic blood pressure <90 mmHg and/or prolonged requirement for vasopressor use. (NCT00141778)
Timeframe: Measured during and after surgery, until discharge, from 5.7 to 6.8 days on average.

Length of Hospital Stay (Days)

Intervention	percentage of patients (Number)
Placebo	5.4
Ramipril	10.6
Spironolactone	10.2

(NCT00141778)
Timeframe: Measured from the day of surgery until the time of hospital discharge

Postoperative Atrial Fibrillation

Intervention	days (Mean)
Placebo	6.8
Ramipril	5.7
Spironolactone	5.8

The primary endpoint of the study was the percentage of patients with electrocardiographically confirmed AF of at least 10 secs duration at any time following the end of surgery until hospital discharge, an average from 5.7 days in the ramipril group to 6.8 days in the placebo group. Patients were monitored continuously on telemetry throughout the postoperative period until discharge. Electrocardiograms were obtained for any rhythm changes detected on telemetry monitoring, and in addition, electrocardiograms were performed preoperatively, at admission to the intensive care unit, and daily starting on postoperative day 1. All electrocardiograms and rhythm strips were reviewed in a blinded fashion by a single cardiac electrophysiologist. (NCT00141778)
Timeframe: Measured from admission to the ICU until discharge from hospital

Stroke

Intervention	percentage of patients (Number)
Placebo	27.2
Ramipril	27.8
Spironolactone	25.9

Percentage of patients in each study group who experience a cerebrovascular event, confirmed by CT. (NCT00141778)
Timeframe: Measured until the time of hospital discharge, from 5.7 to 6.8 days on average depending on the study arm.

Time to Tracheal Extubation

Intervention	percentage of patients (Number)
Placebo	2.7
Ramipril	1.3
Spironolactone	2.0

It is the time in minutes that it took to extubate the patient after surgery. (NCT00141778)
Timeframe: It is the time (in minutes) from admission to the ICU until tracheal extubation

Perioperative C-reactive Protein (CRP) Concentrations

Intervention	minutes (Mean)
Placebo	1091.3
Ramipril	970.1
Spironolactone	576.4

C-reactive protein was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period

Perioperative Interleukin(IL)-6 Concentrations

Intervention	ug/mL (Mean)
	Initiation of surgery	Postoperative day 1	Postoperative day 2	Postoperative day 3	Postoperative day 4
Placebo	4.1	51.4	134.8	128.3	94.1
Ramipril	4.3	49.9	131.0	164.8	105.2
Spironolactone	3.9	64.3	127.8	189.4	126.5

Interleukin-6 was measured at several time points (see time points in table) over the course of the study (NCT00141778)
Timeframe: Perioperative period

Perioperative Plasminogen Activator Inhibitor-1 (PAI-1) Concentrations

Intervention	pg/ml (Mean)
	Initiation of surgery	30min intraop	60min intraop	Postop	Postoperative day 1	Postoperative day 2
Placebo	4.7	12.0	15.6	130.0	119.0	100.3
Ramipril	4.6	20.5	28.8	202.1	171.0	95.5
Spironolactone	6.6	11.3	17.4	145.7	164.9	109.6

Plasminogen activator inhibitor-1 (PAI-1) was measured at several time points (see table) over the course of the study. (NCT00141778)
Timeframe: Perioperative period

Intervention	ng/mL (Mean)
	Initiation of surgery	30min intraop	60min intraop	Postop	Postoperative day 1	Postoperative day 2
Placebo	19.6	19.2	21.0	36.4	55.2	28.1
Ramipril	16.2	19.7	22.0	38.9	47.9	25.7
Spironolactone	17.3	17.3	20.1	34.0	48.9	31.0

Article	Year
3,4-Dihydroquinolin-2(1H)-ones as combined inhibitors of thromboxane A2 synthase and cAMP phosphodiesterase. Journal of medicinal chemistry, 1992, Feb-21, Volume: 35, Issue:4 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 6-Ketoprostaglandin F1 alpha; Adenosine Diphosphate; Animals; A	1992
Induced Hypertension or Intravenous Milrinone for Cerebral Vasospasm: Why Choose? Neurocritical care, 2021, Volume: 35, Issue:3 Topics: Cerebral Angiography; Humans; Hypertension; Milrinone; Subarachnoid Hemorrhage; Vasospasm, Intracran	2021
Role of Induced Hypertension and Intravenous Milrinone After Aneurysmal Subarachnoid Hemorrhage: Is it Time to Shift the Paradigm? Neurocritical care, 2021, Volume: 35, Issue:3 Topics: Cerebral Angiography; Humans; Hypertension; Milrinone; Subarachnoid Hemorrhage; Vasospasm, Intracran	2021
Milrinone effects on cardiac mitochondria, hemodynamics, and death in catecholamine-infused rats. Pediatric research, 2022, Volume: 92, Issue:5 Topics: Animals; Cardiotonic Agents; Catecholamines; Heart Failure; Hemodynamics; Hypertension; Male; Milrin	2022
Hemodynamic response and clinical outcome following intravenous milrinone plus norepinephrine-based hyperdynamic hypertensive therapy in patients suffering secondary cerebral ischemia after aneurysmal subarachnoid hemorrhage. Acta neurochirurgica, 2022, Volume: 164, Issue:3 Topics: Brain Ischemia; Cerebral Infarction; Hemodynamics; Humans; Hypertension; Milrinone; Nimodipine; Nore	2022
Neonatal circulatory failure due to acute hypertensive crisis: clinical and echocardiographic clues. Cardiovascular journal of Africa, 2013, Volume: 24, Issue:3 Topics: Acute Disease; Antihypertensive Agents; Aortic Valve Insufficiency; Arterial Pressure; Body Weight;	2013
Increased cAMP signaling can ameliorate the hypertensive condition in spontaneously hypertensive rats. Journal of vascular research, 2009, Volume: 46, Issue:1 Topics: Adenylate Cyclase Toxin; Animals; Aorta; Blood Pressure; Cardiac Output; Cyclic AMP; Cyclic Nucleoti	2009
Postrenal biopsy AVM leading to severe hypertension and dilated cardiomyopathy. Pediatric nephrology (Berlin, Germany), 2009, Volume: 24, Issue:12 Topics: Arteriovenous Fistula; Arteriovenous Malformations; Biopsy; Cardiomyopathy, Dilated; Cardiotonic Age	2009
Treatment of milrinone-associated tachycardia with beta-blockers. Canadian journal of anaesthesia = Journal canadien d'anesthesie, 1998, Volume: 45, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Anesthesia, Epidural; Anesthesia, General; Anti-Arrhythmia Agents	1998
Systolic time intervals as indicators for cardiac function in rat models for heart failure. European heart journal, 1990, Volume: 11 Suppl I Topics: Age Factors; Animals; Blood Flow Velocity; Captopril; Cardiac Output; Cardiotonic Agents; Dobutamine	1990

milrinone and Blood Pressure, High